PHIBRO ANIMAL HEALTH CORP-A (PAHC) Stock Fundamental Analysis
NASDAQ:PAHC - Nasdaq - US71742Q1067 - Common Stock - Currency: USD
We assign a fundamental rating of 6 out of 10 to PAHC. PAHC was compared to 193 industry peers in the Pharmaceuticals industry. While PAHC belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. PAHC may be a bit undervalued, certainly considering the very reasonable score on growth
1. Profitability
1.1 Basic Checks
PAHC had positive earnings in the past year.
In the past year PAHC had a positive cash flow from operations.
In the past 5 years PAHC has always been profitable.
Each year in the past 5 years PAHC had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PAHC (2.41%) is better than 83.94% of its industry peers.
Looking at the Return On Equity, with a value of 11.95%, PAHC belongs to the top of the industry, outperforming 88.08% of the companies in the same industry.
PAHC has a better Return On Invested Capital (9.33%) than 87.05% of its industry peers.
The Average Return On Invested Capital over the past 3 years for PAHC is significantly below the industry average of 14.98%.
The last Return On Invested Capital (9.33%) for PAHC is above the 3 year average (7.71%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.41% | ||
| ROE | 11.95% | ||
| ROIC | 9.33% |
ROA(3y)2.96%
ROA(5y)3.93%
ROE(3y)10.41%
ROE(5y)14.38%
ROIC(3y)7.71%
ROIC(5y)8.07%
1.3 Margins
Looking at the Profit Margin, with a value of 2.67%, PAHC belongs to the top of the industry, outperforming 83.42% of the companies in the same industry.
In the last couple of years the Profit Margin of PAHC has declined.
PAHC has a Operating Margin of 10.42%. This is amongst the best in the industry. PAHC outperforms 81.87% of its industry peers.
PAHC's Operating Margin has declined in the last couple of years.
PAHC has a Gross Margin (32.27%) which is in line with its industry peers.
In the last couple of years the Gross Margin of PAHC has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.42% | ||
| PM (TTM) | 2.67% | ||
| GM | 32.27% |
OM growth 3Y-6.57%
OM growth 5Y-5.77%
PM growth 3Y-66.87%
PM growth 5Y-48.58%
GM growth 3Y-1.82%
GM growth 5Y-0.72%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PAHC is creating some value.
PAHC has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for PAHC remains at a similar level compared to 5 years ago.
PAHC has a worse debt/assets ratio than last year.
2.2 Solvency
PAHC has an Altman-Z score of 2.59. This is not the best score and indicates that PAHC is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.59, PAHC is doing good in the industry, outperforming 70.47% of the companies in the same industry.
PAHC has a debt to FCF ratio of 14.83. This is a negative value and a sign of low solvency as PAHC would need 14.83 years to pay back of all of its debts.
PAHC has a better Debt to FCF ratio (14.83) than 79.79% of its industry peers.
PAHC has a Debt/Equity ratio of 2.67. This is a high value indicating a heavy dependency on external financing.
With a Debt to Equity ratio value of 2.67, PAHC is not doing good in the industry: 80.31% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 14.83 | ||
| Altman-Z | 2.59 |
ROIC/WACC1.06
WACC8.76%
2.3 Liquidity
PAHC has a Current Ratio of 2.91. This indicates that PAHC is financially healthy and has no problem in meeting its short term obligations.
PAHC has a Current ratio (2.91) which is comparable to the rest of the industry.
A Quick Ratio of 1.23 indicates that PAHC should not have too much problems paying its short term obligations.
The Quick ratio of PAHC (1.23) is worse than 68.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 1.23 |
3. Growth
3.1 Past
PAHC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 66.38%, which is quite impressive.
The Earnings Per Share has been decreasing by -4.78% on average over the past years.
PAHC shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.13%.
PAHC shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.21% yearly.
EPS 1Y (TTM)66.38%
EPS 3Y-2.15%
EPS 5Y-4.78%
EPS Q2Q%103.23%
Revenue 1Y (TTM)19.13%
Revenue growth 3Y6.89%
Revenue growth 5Y4.21%
Sales Q2Q%32.14%
3.2 Future
Based on estimates for the next years, PAHC will show a very strong growth in Earnings Per Share. The EPS will grow by 26.95% on average per year.
PAHC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 2.87% yearly.
EPS Next Y74.86%
EPS Next 2Y41.42%
EPS Next 3Y31.12%
EPS Next 5Y26.95%
Revenue Next Year27.22%
Revenue Next 2Y19.96%
Revenue Next 3Y14.04%
Revenue Next 5Y2.87%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
PAHC is valuated correctly with a Price/Earnings ratio of 14.67.
Based on the Price/Earnings ratio, PAHC is valued cheaply inside the industry as 86.01% of the companies are valued more expensively.
PAHC's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.54.
Based on the Price/Forward Earnings ratio of 11.90, the valuation of PAHC can be described as reasonable.
Based on the Price/Forward Earnings ratio, PAHC is valued cheaper than 81.87% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of PAHC to the average of the S&P500 Index (35.28), we can say PAHC is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.67 | ||
| Fwd PE | 11.9 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PAHC indicates a rather cheap valuation: PAHC is cheaper than 85.49% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, PAHC is valued cheaply inside the industry as 81.87% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 23.4 | ||
| EV/EBITDA | 10.54 |
4.3 Compensation for Growth
PAHC's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PAHC may justify a higher PE ratio.
A more expensive valuation may be justified as PAHC's earnings are expected to grow with 31.12% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y31.12%
5. Dividend
5.1 Amount
PAHC has a Yearly Dividend Yield of 1.81%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 4.15, PAHC pays a better dividend. On top of this PAHC pays more dividend than 91.19% of the companies listed in the same industry.
Compared to the average S&P500 Dividend Yield of 2.40, PAHC is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
5.2 History
The dividend of PAHC has a limited annual growth rate of 0.87%.
PAHC has been paying a dividend for at least 10 years, so it has a reliable track record.
PAHC has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)0.87%
Div Incr Years0
Div Non Decr Years10
5.3 Sustainability
PAHC pays out 61.17% of its income as dividend. This is not a sustainable payout ratio.
PAHC's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP61.17%
EPS Next 2Y41.42%
EPS Next 3Y31.12%
NASDAQ:PAHC (8/8/2025, 3:03:46 PM)
28.32
+0.99 (+3.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.89%
Inst Owner Change-3.8%
Ins Owners0.45%
Ins Owner Change23.26%
Market Cap1.15B
Analysts45
Price Target22.95 (-18.96%)
Short Float %4.11%
Short Ratio2.94
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.81% |
Yearly Dividend0.48
Dividend Growth(5Y)0.87%
DP61.17%
Div Incr Years0
Div Non Decr Years10
Ex-Date
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.67%
Min EPS beat(2)18.78%
Max EPS beat(2)24.57%
EPS beat(4)4
Avg EPS beat(4)25.71%
Min EPS beat(4)18.78%
Max EPS beat(4)38.92%
EPS beat(8)6
Avg EPS beat(8)9.99%
EPS beat(12)7
Avg EPS beat(12)1.59%
EPS beat(16)9
Avg EPS beat(16)0.35%
Revenue beat(2)0
Avg Revenue beat(2)-1.72%
Min Revenue beat(2)-3.24%
Max Revenue beat(2)-0.2%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-3.24%
Max Revenue beat(4)4.46%
Revenue beat(8)4
Avg Revenue beat(8)-0.44%
Revenue beat(12)6
Avg Revenue beat(12)-0.41%
Revenue beat(16)10
Avg Revenue beat(16)0.59%
PT rev (1m)15.38%
PT rev (3m)18.42%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.11%
EPS NY rev (1m)-0.49%
EPS NY rev (3m)5.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.28%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.67 | ||
| Fwd PE | 11.9 | ||
| P/S | 0.96 | ||
| P/FCF | 23.4 | ||
| P/OCF | 13.15 | ||
| P/B | 4.32 | ||
| P/tB | 6.61 | ||
| EV/EBITDA | 10.54 |
EPS(TTM)1.93
EY6.81%
EPS(NY)2.38
Fwd EY8.4%
FCF(TTM)1.21
FCFY4.27%
OCF(TTM)2.15
OCFY7.6%
SpS29.38
BVpS6.56
TBVpS4.28
PEG (NY)0.2
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 2.41% | ||
| ROE | 11.95% | ||
| ROCE | 11.8% | ||
| ROIC | 9.33% | ||
| ROICexc | 9.99% | ||
| ROICexgc | 11.03% | ||
| OM | 10.42% | ||
| PM (TTM) | 2.67% | ||
| GM | 32.27% | ||
| FCFM | 4.12% |
ROA(3y)2.96%
ROA(5y)3.93%
ROE(3y)10.41%
ROE(5y)14.38%
ROIC(3y)7.71%
ROIC(5y)8.07%
ROICexc(3y)8.81%
ROICexc(5y)9.3%
ROICexgc(3y)10.51%
ROICexgc(5y)11.41%
ROCE(3y)9.76%
ROCE(5y)10.21%
ROICexcg growth 3Y-6.09%
ROICexcg growth 5Y-7.6%
ROICexc growth 3Y-4.3%
ROICexc growth 5Y-7.55%
OM growth 3Y-6.57%
OM growth 5Y-5.77%
PM growth 3Y-66.87%
PM growth 5Y-48.58%
GM growth 3Y-1.82%
GM growth 5Y-0.72%
F-Score5
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.67 | ||
| Debt/FCF | 14.83 | ||
| Debt/EBITDA | 4.27 | ||
| Cap/Depr | 90.16% | ||
| Cap/Sales | 3.21% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 52.44% | ||
| Profit Quality | 154.31% | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 1.23 | ||
| Altman-Z | 2.59 |
F-Score5
WACC8.76%
ROIC/WACC1.06
Cap/Depr(3y)126.5%
Cap/Depr(5y)115.35%
Cap/Sales(3y)4.43%
Cap/Sales(5y)4.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)66.38%
EPS 3Y-2.15%
EPS 5Y-4.78%
EPS Q2Q%103.23%
EPS Next Y74.86%
EPS Next 2Y41.42%
EPS Next 3Y31.12%
EPS Next 5Y26.95%
Revenue 1Y (TTM)19.13%
Revenue growth 3Y6.89%
Revenue growth 5Y4.21%
Sales Q2Q%32.14%
Revenue Next Year27.22%
Revenue Next 2Y19.96%
Revenue Next 3Y14.04%
Revenue Next 5Y2.87%
EBIT growth 1Y94%
EBIT growth 3Y-0.14%
EBIT growth 5Y-1.81%
EBIT Next Year173.95%
EBIT Next 3Y45.1%
EBIT Next 5Y14.26%
FCF growth 1Y184.37%
FCF growth 3Y34.65%
FCF growth 5Y21.82%
OCF growth 1Y1728.38%
OCF growth 3Y21.94%
OCF growth 5Y13.18%